Taiyen Biotech Co., Ltd.

TWSE:1737 Stock Report

Market Cap: NT$6.5b

Taiyen Biotech Balance Sheet Health

Financial Health criteria checks 5/6

Taiyen Biotech has a total shareholder equity of NT$6.6B and total debt of NT$194.8M, which brings its debt-to-equity ratio to 3%. Its total assets and total liabilities are NT$8.2B and NT$1.7B respectively. Taiyen Biotech's EBIT is NT$303.5M making its interest coverage ratio -9.7. It has cash and short-term investments of NT$1.8B.

Key information

3.0%

Debt to equity ratio

NT$194.84m

Debt

Interest coverage ratio-9.7x
CashNT$1.78b
EquityNT$6.55b
Total liabilitiesNT$1.68b
Total assetsNT$8.23b

Recent financial health updates

Recent updates

Taiyen Biotech's (TWSE:1737) Dividend Will Be Reduced To NT$1.20

Jul 31
Taiyen Biotech's (TWSE:1737) Dividend Will Be Reduced To NT$1.20

Investors Can Find Comfort In Taiyen Biotech's (TWSE:1737) Earnings Quality

May 09
Investors Can Find Comfort In Taiyen Biotech's (TWSE:1737) Earnings Quality

Taiyen Biotech (TPE:1737) Has A Pretty Healthy Balance Sheet

Apr 24
Taiyen Biotech (TPE:1737) Has A Pretty Healthy Balance Sheet

Taiyen Biotech's (TPE:1737) Returns On Capital Are Heading Higher

Apr 09
Taiyen Biotech's (TPE:1737) Returns On Capital Are Heading Higher

A Look At The Intrinsic Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

Mar 25
A Look At The Intrinsic Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

Is Taiyen Biotech Co., Ltd. (TPE:1737) Popular Amongst Institutions?

Mar 12
Is Taiyen Biotech Co., Ltd. (TPE:1737) Popular Amongst Institutions?

Taiyen Biotech Co., Ltd. (TPE:1737) Stock's On A Decline: Are Poor Fundamentals The Cause?

Feb 14
Taiyen Biotech Co., Ltd. (TPE:1737) Stock's On A Decline: Are Poor Fundamentals The Cause?

Taiyen Biotech Co., Ltd. (TPE:1737) Investors Should Think About This Before Buying It For Its Dividend

Feb 01
Taiyen Biotech Co., Ltd. (TPE:1737) Investors Should Think About This Before Buying It For Its Dividend

Taiyen Biotech (TPE:1737) Seems To Use Debt Quite Sensibly

Jan 17
Taiyen Biotech (TPE:1737) Seems To Use Debt Quite Sensibly

Returns On Capital - An Important Metric For Taiyen Biotech (TPE:1737)

Jan 04
Returns On Capital - An Important Metric For Taiyen Biotech (TPE:1737)

A Look At The Fair Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

Dec 22
A Look At The Fair Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

How Much Of Taiyen Biotech Co., Ltd. (TPE:1737) Do Institutions Own?

Dec 09
How Much Of Taiyen Biotech Co., Ltd. (TPE:1737) Do Institutions Own?

Shareholders Of Taiyen Biotech (TPE:1737) Must Be Happy With Their 53% Return

Nov 24
Shareholders Of Taiyen Biotech (TPE:1737) Must Be Happy With Their 53% Return

Financial Position Analysis

Short Term Liabilities: 1737's short term assets (NT$2.8B) exceed its short term liabilities (NT$1.0B).

Long Term Liabilities: 1737's short term assets (NT$2.8B) exceed its long term liabilities (NT$653.6M).


Debt to Equity History and Analysis

Debt Level: 1737 has more cash than its total debt.

Reducing Debt: 1737's debt to equity ratio has increased from 0.3% to 3% over the past 5 years.

Debt Coverage: 1737's debt is well covered by operating cash flow (272.4%).

Interest Coverage: 1737 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies